Intuitive Surgical Inc.

NASDAQ · ISRG
432.01−16.75−3.73%as of Oct 30, 2026

As part of Intuitive’s mission, we believe that minimally invasive care is life-enhancing care. By combining ingenuity and intelligent technology, we expand the potential of physicians to heal without constraints. We envision a future of care that is less invasive and profoundly better, where diseases are identified early and treated quickly so patients can get back to what matters most. Since our founding over 30 years ago, we have been delivering on this mission and vision by combining innovative technology with clinical expertise to advance minimally invasive care. We do so by providing a comprehensive ecosystem that includes robotic-assisted systems, instruments and accessories, customer learning, and customer support services all connected by a digital portfolio that enables actionable insights across the care continuum. Among other capabilities, these products and services can augment the skills and improve the efficiency of clinicians and care teams while providing decision support and learning that can help deliver differentiated clinical and economic value for patients, providers, and payers when compared to the next best available treatment options. To assure continued al

From the 10-K filed Feb 3, 2026

CEO
Mr. David J. Rosa
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
17,021
Headquarters
Sunnyvale, CA
Fiscal year end
December
1 year−98.01 (−18.49%)
ISRG−18.49%
$350$400$450$500$550$600
$432.01
20MVol
Oct '25Jan '26Mar '26Jun '26Aug '26Oct '26
FundalyzePowered by fundalyze.ai
328.57603.88

as of Oct 22, 2026 · today 432.01, 38% of the way from low to high

No dividends on record.

A company that pays none, or whose history has not arrived yet, shows nothing here.

Valuation

Market cap$152.89Bas of Oct 22, 2026
P/E51.7×TTM · Q4 2025 – Q3 2026
P/S13.2×TTM · Q4 2025 – Q3 2026
P/B9.6×Q3 2026
Dividend yield—no dividends on record

Results, trailing twelve months

Revenue$11.58BTTM · Q4 2025 – Q3 2026
Net income$2.96BTTM · Q4 2025 – Q3 2026
Diluted EPS$8.41TTM · Q4 2025 – Q3 2026
Gross margin67.2%TTM · Q4 2025 – Q3 2026

Balance and cash

Enterprise value$149.91Bas of Oct 22, 2026
Long-term debt—
Free cash flow$3.60BTTM · Q4 2025 – Q3 2026
Stock-based comp.$835.30MTTM · Q4 2025 – Q3 2026

Shares and market

Shares outstanding353.90Mas of Oct 30, 2026
Average volume2.85Mshares a day, last 3 months
Beta1.463

Financial statements

Total revenue +20.5% $8.35B → $10.06B, year ended Dec 31, 2025

Comps

Valuation, growth and margins against the closest competitors

Filings

10-K filed Feb 3, 2026 · 10-Q Oct 21, 2026

FilingFiled
10-Q for Quarter Ended September 2026Oct 21, 2026
10-Q for Quarter Ended June 2026Jul 21, 2026
10-Q for Quarter Ended March 2026Apr 22, 2026
10-K for Fiscal Year Ended December 2025Feb 3, 2026

Insiders

$66.62M sold open market, 12 months to Oct 28, 2026

InsiderTypeValue
Mark BrosiusOct 28, 2026Sale$26.94K ↗
Mark BrosiusOct 27, 2026Sale$27.55K ↗
Mark BrosiusOct 26, 2026Sale$27.56K ↗
Gary S GuthartOct 23, 2026Sale$9.08M ↗

Funds (13F)

87.2% held by 2,296 managers · as of Sep 30, 2026

ManagerValueChange
BlackRock, Inc.$11.94B−51.26K (−0.2%)
VANGUARD CAPITAL MANAGEMENT LLC$9.20B+51.61K (+0.2%)
STATE STREET CORP$6.39B+216.07K (+1.4%)
Invesco Ltd.$4.71B+653.08K (+5.8%)
PRICE T ROWE ASSOCIATES INC /MD/$4.48B−1.26M (−10.1%)

Congress

30 trades 12 sales · 18 purchases · 5 members, 12 months

MemberTypeAmount
Ro KhannaSep 25, 2026Purchase$1K–$15K
Ro KhannaSep 11, 2026Purchase$1K–$15K
Ro KhannaSep 4, 2026Purchase$1K–$15K
Ro KhannaAug 24, 2026Purchase$1K–$15K

Short interest

2.13% of float · 4.05 days to cover · Oct 15, 2026

Short position, last two years · 81% of its 2-year range

Source: FINRA

Headlines indexed by The GDELT Project ↗, matched by company name, so one may be about something else. Each opens on its publisher’s site.

Company data reported to the SEC on EDGAR (CIK 1035267).

Everything on ISRG, in full

Every fiscal year and quarter as filed, the filing reader with highlights and AI summaries, insider and fund activity, congressional trades, short interest history, earnings calls, the full price history and every peer. A 7-day free trial, then a subscription.

Start your free trial